Table 4.
Literature review
| RT dose (Gy) | ADT rate (%) | ADT duration (M) | PSA relapse-free survival (%) | |||
|---|---|---|---|---|---|---|
| Alicikus et al.
[1] |
81 |
LR |
54 (total) |
3 |
PD: 10-year |
81 |
| |
IR |
|
|
|
78 |
|
| |
HR |
|
|
|
62 |
|
| Martin et al.
[4] |
79.8 |
LR |
13.6 |
not mentioned |
PD: 5-year |
88.4 |
| |
|
IR |
11.0 |
|
|
76.5 |
| |
HR |
45.9 |
|
|
77.9 |
|
| Zelefsky et al.
[12] |
81 |
LR |
33.5 |
3 |
AD: 8-year |
85 |
| |
IR |
52 |
|
|
76 |
|
| |
HR |
92 |
|
|
72 |
|
| |
LR |
33.5 |
|
PD: 8-year |
89 |
|
| |
IR |
52 |
|
|
78 |
|
| |
HR |
92 |
|
|
67 |
|
| Cahlon, et al.
[16] |
86.4 |
LR |
66 (total) |
3 or 9 |
PD: 5-year |
98 |
| |
IR |
|
|
|
85 |
|
| |
HR |
|
|
|
70 |
|
| Current study |
80 or 76 |
IR |
67 |
5 (median) (range: 4–32) |
PD: 5-year |
100 |
| HR | 95 | 12 (median) (range: 2–88) | 82.2 | |||
Abbreviations: RT, radiotherapy; M, months; LR, low risk; PD, Phoenix Consensus definition; AD, American Society for Therapeutic Radiology and Oncology definition; other abbreviations as in Table 1.